AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04658680
Drug: BCG vaccination at first health facility contact
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal injection at first health facility contact: 0.05 ml dose Mycobacterium bovis BCG live attenuated vaccine in the left deltoid region.~The strain supplied by the national vaccination programme is provided through UNICEF. Different strains are used interchangeably. The additional BCG vaccines provided through this study will be procured by the Bandim Health Project. Vaccines will be from the WHO list of prequalified vaccines and the same strain will be used in intervention and control health centres.
Trial: NCT05657171
Drug: cyproterone Acetate/Ethinyl Estradiol Combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cyproterone acetate (CPA) 2 mg, combined with EE 35 µg.
Trial: NCT05642845
Drug: Liprimar® film-coated tablet 40 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liprimar® is manufactured by Pfizer Pharmaceuticals LLC, Puerto Rico, LLC Polysan Scientific and Technological Pharmaceutical Firm; RU holder: Pfizer Inc, USA. Each tablet contains 40 mg of atorvastatin.
Trial: NCT06636825
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400 mg caffeine capsule taken in a single dose 1 hour prior to graded hypercapnia
Trial: NCT06636825
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (microcrystalline cellulose) capsule taken in a single dose 1 hour prior to graded hypercapnia
Trial: NCT06170242
Drug: EDP-323 Dose Regimen 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EDP-323 capsule
Trial: NCT06170242
Drug: EDP-323 Dose Regimen 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EDP-323 capsule
Trial: NCT06170242
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule
Trial: NCT05917964
Drug: LP-168 tablet
RxNorm normalized name: LP-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LP-168 is a small molecule kinase inhibitor that is administered once daily via oral administration
Trial: NCT05746273
Drug: Transdermal Placebo Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will wear placebo transdermal patches daily for 12-15 weeks. They will apply a study patch each morning and remove at bedtime. Placebo patch dose will titrate up from 3.5mg to 7mg, and then can optionally be further titrated to a maximum dose of 14mg. After week12, the dose will be slowly tapered over 2-3 weeks.
Trial: NCT05960201
Drug: [18F]fluoroestradiol (FES)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F-18 FES 111\~222 MBq(megabecquerel) injection
Trial: NCT06137092
Drug: Factor VIII, recombinant human with Fc fusion (rFVIII-Fc)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rFVIII-Fc, IV, 50 units/kg/ single dose, cross-over
Trial: NCT06468943
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 750mg/㎡/21d（d1） Intravenous infusion
Trial: NCT06468943
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50mg/㎡/21d（d1） Intravenous infusion
Trial: NCT04722679
Drug: Non-VKA Oral Anticoagulants (NOAC)
RxNorm normalized name: Tavist Non-Sedating Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Follow clinical practice.
Trial: NCT05607589
Drug: DWP213388
FDA approved: no
EMA approved: no
PMDA approved: no
Description: immunosuppressant
Trial: NCT05360602
Drug: The standard care for post-PCI MI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: will include the required antiplatelet (Dual Antiplatelet Therapy; DAPT), anticoagulants, and anti-ischemic measures (high-intensity statin, ACEI, or aldosterone) as per latest guidelines recommendations.
Trial: NCT06255340
Drug: Placebo matching BI 3031185
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT06491576
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: taking the placebo orally
Trial: NCT06644404
Drug: DWP16001 0.3mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet, Orally, Once daily single dose
Trial: NCT06644404
Drug: DWC202407 1,000mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet, Orally, Twice daily
Trial: NCT06644404
Drug: DWC202408 2mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet, Orally, Once daily single dose
Trial: NCT06253611
Drug: FOLFOX regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaliplatin 85 mg/m², leucovorin 400 mg/m², bolus of 5-FU 400 mg/m², continuous 5-FU 2400/m² in 46 hours; every 2 weeks
Trial: NCT06674291
Drug: No intervention (observational study)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is an observational registry conducted in the real world clinical setting and there is no intervention in this study. Treatment of MDR-END Regimen and the follow-up of subjects will be conducted in the clinical judgment of the investigator.
Trial: NCT03261375
Drug: Antihypertensive Agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium channel blocker, Diuretic
Trial: NCT06376110
Drug: Topical Antioxidant Serum
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An oil-free vitamin C serum for oily skin and blemish-prone skin that delivers advanced environmental protection, reduces oiliness, refines skin texture, and visibly improves skin clarity and fine lines.
Trial: NCT05411900
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will consist of equal volume of saline solution (0.9%). Injections will be repeated at sites 1-1.5 cm apart (0.1 ml, 16.6 units per site), up to 20 sites (333 units).~To reduce pain caused by the injection, lidocaine and prilocaine cream will be applied to the skin area 60 min before the procedure. Additionally, ice could be applied for a few seconds (4-8) before each injection.~Injections will be repeated at week 0 and week 12.~The active treatment and placebo solutions will be transparent and indistinguishable to maintain treatment blindness.
Trial: NCT06635850
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo for inhalation
Trial: NCT06293287
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo (0.9% saline solution)
Trial: NCT05451329
Drug: VVN539 Ophthalmic Solution 0.02%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once a day \[q.d.\] in the morning, q.d. in the evening and twice a day \[b.i.d.\]) will be tested for 7-9 days
Trial: NCT05451329
Drug: VVN539 Ophthalmic Solution 0.04%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once a day \[q.d.\] in the morning, q.d. in the evening and twice a day \[b.i.d.\]) will be tested for 7-9 days
Trial: NCT05451329
Drug: VVN539 Ophthalmic Solution Vehicle
RxNorm normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once a day \[q.d.\] in the morning, q.d. in the evening and twice a day \[b.i.d.\]) will be tested for 7-9 days
Trial: NCT05611957
Drug: LY3437943
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC.
Trial: NCT05533372
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for oral administration.
Trial: NCT05533372
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate for oral administration.
Trial: NCT05917145
Drug: WSD0628
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A non-toxic compound and inhibits the DNA damage response associated with radiation therapy. • WSD-0628 radio sensitizes Glioblastoma cells.
Trial: NCT04913090
Drug: Placebo to match XZP-5610 Tablet (for Part A)
RxNorm normalized name: PLACEBO TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet(s) administered orally once daily for 1 Day
Trial: NCT04913090
Drug: Placebo to match XZP-5610 Tablet (for Part B)
RxNorm normalized name: PLACEBO TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet(s) administered orally once daily for 14 Days
Trial: NCT04913090
Drug: XZP-5610 Tablet （for Part C1）
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet(s) administered fasted orally once daily for 1 Day
Trial: NCT04733547
Drug: Replacement of fluid loss after graft procurement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediately after the graft procurement, 500 ml of 6% hydroxyethyl starch are infused over 25 minutes. Afterward, Plasmalyte is infused at a rate of 10 ml/min until the end of surgery.
Trial: NCT06548971
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in the control group will chew 300mg of placebos as soon as possible after randomization. If swallowing difficulties arise, the placebo can be crushed and administered via a nasogastric tube.
Trial: NCT05657639
Drug: CAV Regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cladribine 5 mg/m2/day , cytarabine 20mg q12h, venetoclax 100mg d1, 200 d2, 400 mg/day from day 3 to day 21.
Trial: NCT05657639
Drug: MEC Regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitoxantrone 8mg/m2 d1-5, etoposide 100mg/m2 d1-5, cytarabine 1g/m2 d1-5
Trial: NCT05069740
Drug: Salsalate Pill
RxNorm normalized name: salsalate Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salsalate acts as an NFkB inhibitor to reduce systemic inflammation
Trial: NCT05069740
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for the salsalate intervention
Trial: NCT04818229
Drug: Placebo-matched CBP-307
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-matched CBP-307 capsules oral administration.
Trial: NCT05767086
Drug: Gonadotropin releasing hormone antagonist (Cetrotide)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: clinical pregnancy rates
Trial: NCT05029999
Drug: PLD Chemotherapy
RxNorm normalized name: pLDLR-Neo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLD chemotherapy will be administered 40 mg/m2 as intravenous injection once per cycle.
Trial: NCT05105061
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IM injection of matching placebo
Trial: NCT06188975
Drug: DRUG: ABBV-CLS-484
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06674252
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT06675851
Drug: WELLBUTRIN SR (Bupropion HCI) Sustained-Release Tablets, 150 mg; GlaxoSmithKline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupropion 150 mg daily after baseline PET/MRI or MRI/MRS over 6-8 weeks
Trial: NCT06681012
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsules are to be taken twice a day for 2 months (two capsules in the morning before breakfast and two capsules in the evening before dinner during the first 4 weeks of treatment; one capsule in the morning and one in the evening during the following 4 weeks of treatment).
Trial: NCT06687759
Drug: [14C]MK-1084
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT06627595
Drug: Immunotherapy
RxNorm normalized name: Dog immunotherapy extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be treated in accordance with the guidelines for melanoma treatment.
Trial: NCT05365880
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The active placebo comparator will be provided to participant.
Trial: NCT06089317
Drug: TCM ultrasonic atomization treatment with Dendrobii Caulis (DC)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subjects will receive TCM ultrasonic atomization treatment with the ultrasonic nebulizer (WH-2000, YueHua, China) 6 days a week, once daily, 10 minutes per session, for 4 weeks. The solution for atomization of the DC group is Dendrobii Caulis extracts.~The prescription of the DC group contains Dendrobium (石斛) 35g.~Subjects will be treated with hypromellose 0.3% w/v eye drops four times per day too.
Trial: NCT06089317
Drug: TCM ultrasonic atomization treatment with Houttuynia Cordata (HC)
RxNorm normalized name: Houttuynia cordata top extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subjects will receive TCM ultrasonic atomization treatment with the ultrasonic nebulizer (WH-2000, YueHua, China) 6 days a week, once daily, 10 minutes per session, for 4 weeks. The solution for atomization of the HC group is Heartleaf Houttuynia Herb extracts.~The prescription of the HC group contains Heartleaf Houttuynia Herb(魚腥草) 35g.~Subjects will be treated with hypromellose 0.3% w/v eye drops four times per day too.
Trial: NCT06089317
Drug: Placebo TCM ultrasonic atomization treatment (PA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subjects will receive TCM ultrasonic atomization treatment with the ultrasonic nebulizer (WH-2000, YueHua, China) 6 days a week, once daily, 10 minutes per session, for 4 weeks. The solution for atomization of the PA group is low-concentration compound decoction (5%) same with the CD group.~Subjects will be treated with hypromellose 0.3% w/v eye drops four times per day too.
Trial: NCT05381753
Drug: Tyrosine kinase inhibitors other than avapritinib ( imatinib, sunitinib, et al )
RxNorm normalized name: Avapritinib
DrugBank: Avapritinib (DB15233)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Investigators will decide which TKI to use as well as the dosage, frequency, and duration.
Trial: NCT04020263
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be diluted with Glucose G5%. The reconstitution of Placebo will be performed, as close as possible to the start of the infusion. A continuous infusion of Placebo will be administered over 24 h without bolus, started at a rate of 0.1 μg per kilogram of body weight per minute and, in both the persistence of hypoperfusion signs and in the absence of rate-limiting side effects, will be increased after 2 to 4 hours to a maximum of 0.2 μg per kilogram per minute for a further 20 to 22 hours.
Trial: NCT06289582
Drug: [F-18]DPA714 administration IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: brain PET/MRI imaging after \[F-18\]DPA-714 administration
Trial: NCT04781972
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT04822883
Drug: RL-007
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohorts are 10 mg, 20 mg, 40 mg, and 80 mg with TID dosing
Trial: NCT04822883
Drug: RL-007 Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohorts are 10 mg, 20 mg, 40 mg, and 80 mg with TID dosing
Trial: NCT00450840
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06498180
Drug: Glucocorticoid Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local blockade therapy with Betamethasone Sodium Phosphate Injection (containing 1.4mg Betamethasone equivalent), local use of 1% Triamcinolone Acetate Ointment, and rinsing with 1% Sodium Bicarbonate (avoiding systemic use during visits)
Trial: NCT05631886
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous cyclophosphamide 300 mg/m\^2/day on day -4.
Trial: NCT06318546
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: will be given 0.5 ml of one ampoule (2ml) of 100µg fentanyl (Fentanyl Hameln® 0.1mg/2ml - Sunny pharm) equivalent to 25 µg fentanyl as an adjuvant to 2.2ml hyperbaric Bupivacaine hydrochloride 0.5%
Trial: NCT05430919
Drug: REGN5714
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT05430919
Drug: REGN5715
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT06494644
Drug: AZD6793
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive single dose of AZD6793 on Day 1 in Period 1 and on Day 8 in combination with itraconazole in Period 3.
Trial: NCT05531942
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (Aspirin) given at a dose of 100 mg/d for 90 days.
Trial: NCT06498531
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of equally looking placebo capsules in the morning and in the evening, starting 24 hours before departure to 3600 m.
Trial: NCT05323734
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered
Trial: NCT05593770
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orange film-coated, plain bioconvex tablets orally twice daily for 14 days or 28 doses for fostamatinib. Study medication will be continued as an outpatient if the patient is discharged prior to completing 28 doses.
Trial: NCT05289908
Drug: Folic Acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid 200-400 μg is administered orally once daily, prior to the first intrathecal pemetrexed, until 21 days after the last intrathecal pemetrexed.
Trial: NCT06540209
Drug: Saccharomyces boulardii
RxNorm normalized name: Saccharomyces boulardii
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Children will be give Saccharomyces boulardii for 5 days
Trial: NCT06540209
Drug: Zinc
RxNorm normalized name: Zinc
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc will be given to all children for 5 days
Trial: NCT06643013
Drug: XBD173
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 weeks treatment
Trial: NCT06638970
Drug: Secretome
RxNorm normalized name: gonorrheal urethral secretion human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 ml Injection of secretome for 4 times two weeks apart
Trial: NCT06101667
Drug: Best medical management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best medical management included assessment of vital signs and neurological deficits,airway protection respiratory support,circulation;blood pressure monitoring;nutritional support;complication control;symptomatic treatment;laboratory and imaging examinations;etiological analysis and evaluation; anti platelet（e.g. aspirin,adenosine diphosphate (ADP) receptor inhibitors,Adenosine reuptake inhibitors,Glycoprotein platelet inhibitors）；anticoagulation(e.g. warfarin, rivaroxaban,dabigatran,apixaban,edoxaban)；lipid lowering(e.g. Statins,Fibrates）；control of blood pressure(e.g. Thiazide diuretics,Potassium-sparing,Loop diuretic,Beta-blockers,Angiotensin II receptor blockers,Calcium channel blockers,Alpha blockers,Central alpha-2 receptor agonists);control of blood glucose(e.g. SULFONYLUREAS (SFUs),GLINIDES,BIGUANIDES,ALPHA-GLUCOSIDASE INHIBITORS: STARCH BLOCKERS,THIAZOLIDINEDIONES,GLP-1 ANALOGS,DPP-4 INHIBITORS,SGLT2 inhibitors); control of other risk factors
Trial: NCT05474859
Drug: XT-0528
RxNorm normalized name: XT-150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once Daily
Trial: NCT05535972
Drug: FF/UMEC/VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FF/UMEC/VI will be administered in a single inhaler Trelegy Ellipta.
Trial: NCT05752032
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long term follow-up
Trial: NCT06673238
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Capsule
Trial: NCT06687083
Drug: nasal continuous positive pressure ventilation mode
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preterm neonates who will be allocated to this group to the nCPAP will be started on a pressure of 6-8 cm H2O, FiO2) will be adjusted to maintain target oxygen saturation (SpO2) from 92% to 95% by a pulse oximeter
Trial: NCT05691361
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saline
Trial: NCT06439771
Drug: YL202 should be intravenously infused
RxNorm normalized name: Head & Shoulders
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For each patient, YL202 should be intravenously infused over 60±10 min.
Trial: NCT05494619
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered IV on Day 1 at a dose of 1000 mg for participants with body weight ≥ 40 kg to \< 100 kg, or 1500 mg for participants with body weight ≥ 100 kg. It will be administered SC on Days 2, 8, 15, and 22 at a dose 340 mg in all participants.
Trial: NCT05494619
Drug: Intravenous immunoglobulin therapy
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All participants will receive background therapy of IVIg at a dose of 400 milligrams/kilograms (mg/kg) QD for 5 days.
Trial: NCT06570460
Drug: 17-beta estradiol
RxNorm normalized name: 17-beta estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with orally administered estrogen for 6 months
Trial: NCT06570460
Drug: 17-beta estradiol
RxNorm normalized name: 17-beta estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with transdermally administered estrogen for 6 months
Trial: NCT04810676
Drug: CKD-501, D745, D150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QD, PO
Trial: NCT06311734
Drug: LW231 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P.O.
Trial: NCT06311734
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P.O.